Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity
J. D. Kratz, S. Rehman, K. A. Johnson, A. A. Gillette, A. Sunil, P. F. Favreau, C. A. Pasch, D. Miller, L. C. Zarling, A. H. Yeung, L. Clipson, S. J. Anderson, A. K. DeZeeuw, C. M. Sprackling, K. K. Lemmon, , D. A. Deming
The paper evaluates individual patient-derived cancer organoids using optical metabolic imaging to predict therapeutic response and identify subclonal populations and resistance mechanisms.
bioRxiv · Oct 15, 2021 · PreprintCancer Biology